STEM CELLS USED FOR AGE-RELATED MACULAR DEGENERATION
Dr Jenna Hall
Senior Research Associate
University of Melbourne, Victoria, Australia
RESEARCHER PROFILE
Filmed in Melbourne, Australia | January 2025
Dr. Jenna Hall is a passionate and accomplished biologist with expertise in induced pluripotent stem cell (iPSC) culture, disease modelling, and high-throughput automated systems. She recently earned her PhD from the University of Melbourne, where her research focused on using iPSC-derived retinal pigment epithelium (RPE) cells to study age-related macular degeneration. Dr Hall’s technical skillset spans manual and automated cell reprogramming and differentiation, quantitative microscopy-based phenotyping, and large scale -omics analysis.
Dr Hall was awarded a highly competitive and sought after Australian Research Council Centre for Personalised Therapeutics and Technologies (ARC CPTT) scholarship which, in addition to funding her PhD, included an industry internship with a leading life sciences consultancy firm. Her internship with Biointelect allowed her to contribute to strategic projects addressing key challenges in Australia’s biotechnology ecosystem. Her white papers on the country’s vaccine and drug value chain, as well as anti-obesity medication, demonstrated her ability to combine scientific knowledge with commercial insights to influence policy and improve pandemic preparedness.
Dr Hall has over four years of industry experience, including her time at the New York Stem Cell Foundation, where she collaborated with engineers and data scientists to develop scalable workflows for cell reprogramming, downstream differentiation, and automated maintenance. For her next career step, Dr Hall is hoping to secure a role in a fertility research lab.
-
Seeking discoveries in earlier bowel cancer detection
Associate Professor Susan Woods is a cancer research focused on eradicating bowel cancer through earlier detection and investigating the DNA related from colorectal cancer cells. She leads the Gut Cancer Research Group at the University of Adelaide and SAHMRI and with her team is researching new treatments for advanced disease.
-
Professor Sandy Middleton
NURSING RESEARCH INSTITUTE, ST VINCENT’S HEALTH NETWORK SYDNEY, ST VINCENT’S HOSPITAL MELBOURNE AND AUSTRALIAN CATHOLIC UNIVERSITY
NEW SOUTH WALES, AUSTRALIA -
Investigating the benefits of donor human milk for preterm infants
Together, SAHMRI and Lifeblood are leading a consortium to revolutionise the way human milk, and novel products made from human milk, are used as nutritional and medical interventions to improve health outcomes in vulnerable infants, but with potential application for a diverse range of medical indications.
Currently, babies who are born early preterm – before 32 weeks – are given donor milk when their own mother’s milk is not available or in short supply. Whether donor milk is beneficial for babies born just a few weeks early is unclear, as very little research has been undertaken with these babies.
The GIFT Trial will soon commence as an investigation between SAHMRI, the University of Adelaide, the Red Cross Lifeblood Milk Bank conducted at five sites across three states in Australia.
